Phase 1 N=60 Safety and Tolerability of Single and Multiple Doses of Neumifil
Viral Respiratory Tract Infection
Primary: Part A Treatment Emergent Adverse Events — 4; 3; 2; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=494 A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (AUCtau) Between Week 52 and Week 64 — 5144.40; 5768.45 hour*mcg/mL
N/A N=13 Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
Spasmodic Dysphonia · Adductor Spasmodic Dysphonia · Voice Disorders
Primary: Laryngeal Adductor Reflex — 13 Participants
N/A N=193,565 Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
Non-valvular Atrial Fibrillation
Primary: Incidence Rate of a Composite of Recurrent Stroke or Systemic Embolism (SE) During the Follow-up Period: Secondary Prevention (Balanced) Cohort — 41.217; 50.581 Events…
Phase 2 N=14 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings — 13; 13 Participants
Phase 2 N=22 Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Number of Subjects With Progression Free Survival — 6 Participants
Phase 3 N=4,124 Repeat Ivermectin Mass Drug Administrations for MALaria Control II
Malaria
Primary: Malaria Incidence — 0.0176; 0.0183 Malaria cases per person-week
N/A N=1,788 Sientra Sponsored Silimed Gel-Filled Breast Implant Core Clinical Study
Breast Augmentation · Breast Reconstruction · Breast Revision
Primary: Local Complications — 12; 7; 8; 2 Participants
N/A N=167 Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
Tachyarrhythmia · Atrial Fibrillation (AF) · Syncope
Primary: SADE-free Rate Until the 3-month Follow-up — 141 Participants — p=0.05
N/A N=10 Usability Study of OnTrack Tools
Research With Clinical Staff in Stroke Rehabilitation
Primary: System Usability Scale (Phase 1) — 73.3 score on a scale
N/A N=75 Feasibility Trial of the TELL Tool Intervention
Fertility Issues · Disclosure · Parenting
Primary: Number of Participants Who Disclosed the Donor Conception to Their Children — 23; 16 Participants
Phase 2 N=67 A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Gastric Cancer · GastroEsophageal Cancer
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 58.3; 10.5 percentage
N/A N=284 A Clinical Study to Evaluate the Clinical Performance and Safety of LiquiBand FIX8® Versus AbsorbaTack™ for Hernia Mesh Fixation and Peritoneal Closure in Groin Hernia Repair
Hernia · Inguinal Hernia · Femoral Hernia
Primary: Change in Pain — -4.9; -5.1 score on a VAS scale — p=< 0.025
Phase 4 N=10 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Phase 2 N=191 A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma · Follicular Lymphoma
Primary: Part A, Phase I — 0; 1; 3; 0 Participants